In the claims:

1-35. (cancelled)

36. (New) A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:6 and 10.

37. (New) A peptide selected from the group consisting of SEQ ID NOs:6 and 10.

38. (New) A cyclic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 6, 10 and 12, the peptide being no more than 50 amino acid residues in length.

39. (New) The peptide of claim 36, wherein the peptide being no more than 50 amino acid residues in length.

40. (New) The peptide of claim 37, wherein the peptide being no more than 50 amino acid residues in length.

41. (New) A cyclic peptide comprising an amino acid sequence as set forth in SEQ ID NO:27 or 32, wherein the peptide being at least 6 and no more than 50 amino acid residues in length.

42. (New) A peptide comprising an amino acid sequence as set forth in SEQ ID NO:27 or 32, wherein the peptide being at least 6 and no more than 50 amino acid residues in length.

43. (New) The cyclic peptide of claim 41, wherein the amino acid sequence is set forth by SEQ ID NO:2, 6 or 12.

44. (New) A composition-of-matter comprising at least two peptides, each independently selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10 and 12.

45. (New) A pharmaceutical composition comprising as an active ingredient the peptide of claim 42 and a pharmaceutically acceptable carrier or diluent.

46. (New) A pharmaceutical composition comprising as an active ingredient a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 6, 10 and 12, said peptide being no more than 50 amino acid residues in length and a pharmaceutically acceptable carrier or diluent.

47. (New) A method of promoting angiogenesis in a tissue of a subject, the method comprising providing to the subject, a therapeutically effective amount of the peptide of claim 42, to thereby promote angiogenesis in the subject.

48. (New) A method of promoting angiogenesis in a tissue of a subject, the method comprising providing to the subject, a therapeutically effective amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 6, 10 and 12, said peptide being no more than 50 amino acid residues in length, to thereby promote angiogenesis in the subject.

49. (New) A nucleic acid construct comprising a polynucleotide sequence encoding the peptide of claim 36, wherein the peptide is as set forth by SEQ ID NO:6 or 10.

50. (New) A nucleic acid construct comprising a polynucleotide sequence encoding the peptide of claim 37, wherein the peptide is as set forth by SEQ ID NO:6 or 10.

51. (New) A nucleic acid construct comprising a polynucleotide sequence encoding the peptide of claim 41.

52. (New) A nucleic acid construct comprising a polynucleotide sequence encoding the peptide of claim 43.

53. (New) A composition for targeting a drug to endothelial cells, the composition comprising the drug fused to the peptide of claim 37.

54. (New) A composition for targeting a drug to endothelial cells, the composition comprising the drug fused to the peptide of claim 39.

55. (New) A method of identifying putative angiogenic molecules, the method comprising:

(a) providing endothelial cells having peptides bound thereto, each of said peptides having an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 6, 10 and 12, said peptide being no more than 50 amino acid residues in length; and

(b) identifying a molecule capable of displacing said peptides from said endothelial cells, to thereby identify putative angiogenic molecules.

56. (New) The peptide of claim 37, wherein the peptide is a linear peptide.

57. (New) The peptide of claim 42, wherein the peptide is a linear peptide.

58. (New) The pharmaceutical composition of claim 46, wherein the peptide is a linear peptide.

59. (New) The method of claim 48, wherein the peptide is a linear peptide.

60. (New) The peptide of claim 37, wherein the peptide is a cyclic peptide.

61. (New) The peptide of claim 42, wherein the peptide is a cyclic peptide.

62. (New) The pharmaceutical composition of claim 46, wherein the peptide is a cyclic peptide.

63. (New) The method of claim 48, wherein the peptide is a cyclic peptide.

64. (New) The pharmaceutical composition of claim 45, wherein said peptide is a cyclic peptide and whereas said amino acid sequence is selected from the group consisting of SEQ ID NOs:2, 6 and 12.

65. (New) The method of claim 47, wherein said peptide is a cyclic peptide and whereas said amino acid sequence is selected from the group consisting of SEQ ID NOs:2, 6 and 12.

66. (New) The cyclic peptide of claim 41, wherein the peptide is set forth by SEQ ID NOs:2, 6 and/or 12.

67. (New) The peptide of claim 42, wherein the amino acid sequence is set forth by SEQ ID NO:6.

68. (New) The method of claim 47, wherein the subject suffers from arteriosclerosis, retinopathy, remodeling disorder, von Hippel-Lindau syndrome, cerebral ischemia, diabetes and/or hereditary hemorrhagic telengiectasia.

69. (New) The method of claim 48, wherein the subject suffers from arteriosclerosis, retinopathy, remodeling disorder, von Hippel-Lindau syndrome, cerebral ischemia, diabetes and/or hereditary hemorrhagic telengiectasia.